The content on this site is intended for healthcare professionals only
Prof Peter Rothwell speaks to ecancer at the International Aspirin Foundation Scientific Conference 2019 in Rome about the key findings from clinical trials about dosing.
Prof Rothwell explains that there is a lack of modern trials comparing different doses as well as the dosing regimen, but that this is beginning to change.
He also highlights some of the factors to consider when working out the right doses for individual patients.
3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care
Treatment management of favourable risk and very favourable risk patients
Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Geriatric interventions are beneficial in reducing treatment-related toxicity in older adults with cancer
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Gaza's cancer patients: Navigating the dual struggle of illness and war
Cancer in emergencies: What can we do better to protect the most vulnerable?
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
